DANCANN PHARMA DK-0375
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company's development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 Cann… Read more
Market Cap & Net Worth: DANCANN PHARMA DK-0375 (DAN)
DANCANN PHARMA DK-0375 (F:DAN) has a market capitalization of $1.50 Million (€1.46 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #47020 globally and #7850 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DANCANN PHARMA DK-0375's stock price €0.37 by its total outstanding shares 3991100 (3.99 Million).
DANCANN PHARMA DK-0375 Market Cap History: 2021 to 2025
DANCANN PHARMA DK-0375's market capitalization history from 2021 to 2025. Data shows change from $3.29 Million to $1.50 Million (-10.07% CAGR).
DANCANN PHARMA DK-0375 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DANCANN PHARMA DK-0375's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DAN by Market Capitalization
Companies near DANCANN PHARMA DK-0375 in the global market cap rankings as of March 19, 2026.
Key companies related to DANCANN PHARMA DK-0375 by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
DANCANN PHARMA DK-0375 Historical Marketcap From 2021 to 2025
Between 2021 and today, DANCANN PHARMA DK-0375's market cap moved from $3.29 Million to $ 1.50 Million, with a yearly change of -10.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €1.50 Million | +182900.00% |
| 2024 | €819.35 | -93.94% |
| 2023 | €13.52K | -94.31% |
| 2022 | €237.61K | -92.79% |
| 2021 | €3.29 Million | -- |
End of Day Market Cap According to Different Sources
On Feb 27th, 2026 the market cap of DANCANN PHARMA DK-0375 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.50 Million USD |
| MoneyControl | $1.50 Million USD |
| MarketWatch | $1.50 Million USD |
| marketcap.company | $1.50 Million USD |
| Reuters | $1.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.